Billionaires Bet on Pfizer’s Turnaround
Pfizer, one of the world’s most recognized pharmaceutical companies, has been struggling in recent years. Despite its rich history of developing blockbuster drugs, the company’s stock has underperformed the S&P 500 throughout 2024, with shares down nearly 30% over the last three years. However, two billionaire investors, Ken Griffin and Israel Englander, have recently purchased Pfizer stock, sparking interest in the company’s potential turnaround.
The COVID-19 Pandemic’s Impact on Pfizer
Pfizer’s primary source of growth in recent years was its COVID-19 vaccines and treatments. While the company was a leading force against the pandemic, demand for its COVID-19 solutions has decreased significantly as the pandemic appears to be under control. This decline in demand has had a negative impact on Pfizer’s stock performance.
Two Potential Catalysts for Growth
Despite the challenges, there are two potential areas that could help spark a turnaround for Pfizer. Firstly, the company’s acquisition of Seagen, an oncology business, for $43 billion in late 2023 has bolstered its clinical pipeline and augmented its oncology-specific treatments. According to Pfizer, the company hopes to have at least eight blockbuster oncology medications by 2030, up from five today. If executed successfully, this could generate billions of dollars in sales and set the company up for sustained growth.
Secondly, Pfizer is exploring opportunities in the weight loss arena, specifically with Glucagon-like peptide-1 (GLP-1) agonists. While Novo Nordisk and Eli Lilly are currently leading the GLP-1 market, Pfizer is looking to get involved, which could provide a lucrative opportunity for the company.
Why Billionaires Are Investing in Pfizer
It’s worth noting that Citadel and Millennium, the investment firms led by Griffin and Englander, respectively, already have existing positions in Pfizer. Their recent purchases may simply be adding to their existing allocations. Additionally, considering their diversified portfolios, Pfizer may represent a hedge against other peers.
Investing in Pfizer: A Turnaround Story
Investing in Pfizer at its current depressed valuation could be a smart move if the company executes on its new opportunities. However, it’s essential to remember that initiatives involving Seagen will take years to play out, and there is no guarantee of success in the weight loss space. Nevertheless, with investor expectations at an all-time low, Pfizer’s stock may be an attractive option for those willing to take on the risk.
Before investing in Pfizer, it’s crucial to consider the company’s turnaround prospects and your conviction in its ability to diversify further into oncology and potentially enter the weight loss market. As with any investment, it’s essential to do your research and consider your own risk tolerance before making a decision.
Leave a Reply